Surge in Adoption of the Steritas eCOA Suite Continues
Ever since the introduction of the Steritas Glucocorticoid Toxicity Instrument (GTI) in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's ...
Ensuring Data Integrity When the Stakes Are High
When the stakes involve patient outcomes and the credibility of clinical trials in the medical, health and pharmaceutical sectors, maintaining data accuracy, integrity and privacy is essential. In ...
Obexelimab: A New Hope for IgG4-RD Treatment?
Exciting results from an open-label Phase 2 pilot trial published in Lancet Rheumatology[1] suggest that obexelimab, a potential new treatment for IgG4-related disease (IgG4-RD), may become an ...
In Conversation With... John H. Stone, MD MPH
“Steroids have a role in treating so many diseases - and yet, they do not cure any of them.” John H. Stone, MD MPH is a Professor of Medicine at Harvard Medical School, and the Edward A. Fox Chair in ...
TitAIN Trial Provides Hope to Giant Cell Arteritis Patients
A recent phase 2 safety and efficacy study of an anti-interleukin-17A monoclonal antibody for the treatment of giant cell arteritis patients suggests there may soon be another alternative to ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
